SCHEMBL29613045

SCHEMBL29613045

CC(C)[C@H](NS(C)(=O)=O)C(=O)N[C@@H](C)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MME P08473 3/20 0.40
ACE P12821 1/20 0.40
CPA1 P15085 1/20 0.40
ACE2 Q9BYF1 1/20 0.40
CA12 O43570 1/20 0.36
CA14 Q9ULX7 1/20 0.36
ADAM17 P78536 1/20 0.36
CA2 P00918 3/20 0.35
CA1 P00915 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MMP2 P08253 4/20 0.34
MMP13 P45452 4/20 0.34
MMP1 P03956 3/20 0.34
MMP3 P08254 3/20 0.34
MMP9 P14780 3/20 0.34
MMP7 P09237 2/20 0.34
ADAMTS4 O75173 1/20 0.34
MMP8 P22894 1/20 0.34
LTA4H P09960 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19545557 0.87 MME (0.39) MMEACECPA1ACE2ADAM17
SCHEMBL21676278 0.82 CA12 (0.39) CA12CA14ADAM17CA2CA1
SCHEMBL5839741 0.80 KDM4E (0.49) CA12CA14KDM4EMMP2MMP13
SCHEMBL5839738 0.80 KDM4E (0.49) CA12CA14KDM4EMMP2MMP13
SCHEMBL24642687 0.76 MME (0.44) MMEACECPA1ACE2LTA4H
SCHEMBL25628538 0.76 MME (0.44) MMEACECPA1ACE2LTA4H
SCHEMBL25993488 0.76 MME (0.44) MMEACECPA1ACE2LTA4H
SCHEMBL17305532 0.76 MME (0.44) MMEACECPA1ACE2LTA4H
SCHEMBL18047580 0.75 ADAMTS4 (0.44) MMEACECPA1ACE2CA12
SCHEMBL697449 0.75 ADAMTS4 (0.44) MMEACECPA1ACE2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590273-B2 Stabilized glycoside hydrolase variants NOVOZYMES A/S (DK) 2026-03-31 US disclosed
US-12391934-B2 Stabilized cellulase variants NOVOZYMES A/S (DK) 2025-08-19 US disclosed
US-20250084394-A1 STABILIZED CELLULASE VARIANTS NOVOZYMES A/S (DK) 2025-03-13 US disclosed
US-12129498-B2 Stabilized endoglucanase variants NOVOZYMES A/S (DK) 2024-10-29 US disclosed
US-20230295591-A1 STABILIZED CELLULASE VARIANTS NOVOZYMES A/S (DK) 2023-09-21 US disclosed
US-20230287380-A1 STABILIZED CELLULASE VARIANTS NOVOZYMES A/S (DK) 2023-09-14 US disclosed
US-11661592-B2 Stabilized endoglucanase variants NOVOZYMES A/S (DK) 2023-05-30 US disclosed
US-20230143128-A1 CARBOHYDRATE BINDING MODULE VARIANTS NOVOZYMES A/S (DK) 2023-05-11 US disclosed
US-11566239-B2 Stabilized cellulase variants NOVOZYMES A/S (DK) 2023-01-31 US disclosed
US-20220186151-A1 STABILIZED GLYCOSIDE HYDROLASE VARIANTS NOVOZYMES A/S (DK) 2022-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143128-A1 CARBOHYDRATE BINDING MODULE VARIANTS MGAM, MANBA, MAN2B1 MME 139/4885ACE 990/4885CPA1 172/4885
US-12590273-B2 Stabilized glycoside hydrolase variants IDUA, IDE, TREH MME 542/4885ACE 922/4885CPA1 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.